Insiders Updates
Understanding the Risks of Investing in CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG’s filing revealed that its Director George Simeon acquired Company’s shares for reported $51.5 million on Jul 16
Menu
CRISPR Therapeutics AG’s filing revealed that its Director George Simeon acquired Company’s shares for reported $51.5 million on Jul 16
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
In a filing, CRISPR Therapeutics AG revealed its Director George Simeon acquired Company’s shares for reported $51.5 million on Jul
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
In a filing, CRISPR Therapeutics AG revealed its Chief Medical Officer Patel Naimish unloaded Company’s shares for reported $0.14 million
Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. CRISPR Therapeutics
CRISPR Therapeutics AG’s recently made public that its Chief Medical Officer Patel Naimish unloaded Company’s shares for reported $0.14 million
In a filing, CRISPR Therapeutics AG revealed its Chief Medical Officer Patel Naimish unloaded Company’s shares for reported $0.14 million
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or